The expression of VISTA on CD4⁺ T cells is associated with poor prognosis and immune status in non-small cell lung cancer patients

Shengyao Ma¹², Liya Qin¹², Xinling Wang², Weiyu Wang⁷, Jinfeng Li³, Huaijie Wang³, Hanyue Li¹², Xiaoshan Cai³, Yang Yang⁴*, Meihua Qu²*

ABSTRACT

V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a novel negative immune checkpoint considered to be relevant to immunotherapy resistance and a potential target for immunotherapy. In this study, we investigated the relevance of VISTA expression on CD4⁺ T cells and clinical prognosis in non-small cell lung cancer (NSCLC) patients. Tumor tissue samples from 140 NSCLC patients were organized into a tissue microarray. The prognostic value of CD4⁺ VISTA⁺ T cells was analyzed through immunohistochemistry and multicolor fluorescence immunostaining. Fresh tumor tissue samples from 33 NSCLC patients were collected and similarly analyzed to confirm the immune state of patients with VISTA expression on CD4⁺ T cells by flow cytometry. CD4⁺ VISTA⁺ T cells were significantly more infiltrated in tumor tissues. The expression of VISTA on CD4⁺ T cells was correlated with the reduced overall survival of patients with NSCLC and presented a high rate of lymphocyte metastasis. The expression of VISTA on CD4⁺ T cells in tumor tissue showed low secretion of cytokines including IFN-γ, IL-2, IL-4, IL-10, IL-17, and IL-12p70. The expression of VISTA on CD4⁺ T cells could regulate tumor immunity and serve as a prognostic indicator for survival outcomes.

KEYWORDS: VISTA; CD4⁺ T cells; non-small cell lung cancer; prognosis; immune status

INTRODUCTION

In 2020, on an international scale, there was 2.2 million (11.4%) new cases of lung cancer and 1.8 million (18%) deaths [1]. Non-small cell lung cancer (NSCLC) is a major type of primary lung cancer with various histological, genetic, and molecular heterogeneity [2]. Although chemotherapy, targeted therapy, and immunotherapy have been greatly developed in recent years, new immunotherapy targets are urgently required.

The interaction between tumor cells and tumor microenvironment (TME) serves a critical function in tumor occurrence, progression, metastasis, and drug resistance [3,4]. Immune cells in TME could influence the growth and evolution of tumor cells, and the cross-talking of immune cells with tumor cells significantly affects the long-term outcomes in tumor patients [5,6]. Immune checkpoints (ICs) have critical roles in modulating immune responses [7,8]. These inhibitory ICs may be an effective tumor-targeting factor. However, only 20% to 30% of NSCLC patients respond well to immune checkpoint inhibitors [9]. Therefore, the presentation of new ICs and their expression and function would possess value in cancer immunotherapy.

V-domain immunoglobulin suppressor of T-cell activation (VISTA), which was found to be overexpressed in the tumor-infiltrating lymphocytes (TILs) of NSCLC [10], might substantially regulate adaptive antitumor immunity as novel inhibitory ICs [11,12]. CD4⁺ T cells perform crucial roles in initiating, regulating, and adapting immune responses, contributing to the response mediated by B cells and CD8⁺ cytotoxic T cells [13]. The clinical significance and immune microenvironment relevant to VISTA expression on CD4⁺ T cells remain to be further explored in NSCLC. In this study, we studied the relationship between the expression of VISTA on CD4⁺ T cells and the prognosis of NSCLC patients. We tested VISTA expression on CD4⁺ T cells and identified its role in TME with the NSCLC patients’ tumor tissues. The
results showed a correlation with the expression of VISTA on CD4+ T cells and the poor prognosis of NSCLC patients. The expression of VISTA on CD4+ T cells may indicate regulation of tumor immunity.

**MATERIALS AND METHODS**

**Patients, and tissue microarrays**

The tissue samples were collected from patients with lung adenocarcinoma subtype of NSCLC who underwent radical surgery at Weifang Second People’s Hospital from January 1 2011 to December 31 2015. Basis samples were selected randomly upon availability. The pathologist diagnosed the histological type of tumor samples through hematoxylin-eosin (H and E) staining (Supplement Figure 1). A total of 140 tumor tissue samples were organized into tissue microarray chips by Shanghai Outdo Biotech Co., LTD. The clinical and pathological information of the tissue samples were obtained from the Hospital’s information system. The overall survival (OS) was defined as the interval between the date of surgery and date of death or last follow-up. 34 patients had no prognosis and tumor, node, and metastasis (TNM) staging data.

**Immunohistochemistry (IHC)**

IHC was performed on the tissue microarray slides. The tissue microarray slice was cut into 4um and baked in an oven at 60°C for 60 minutes. After dewaxing, hydrogen peroxide blocking, citric acid (BL604A, Biosharp) antigen retrieval, and goat serum (SL038, Solarbio) blocking for 30 minutes at 37°C, the slides were incubated overnight with anti-human VISTA (1:500, ab230950, Abcam) at 4°C. They were then washed by Phosphate Buffered Saline-Tween three times and incubated with Horseradish Peroxidase (HRP)-conjugated secondary antibody for 2 hours at room temperature. Thereafter, the slides were stained with 3, 30-diaminobenzidine (DAB) and counterstained with hematoxylin. The images were scanned with a Panoramic Digital Slide Scanner and analyzed using Panoramic Viewer software.

**Multicolor fluorescence immunostaining**

For multiple-color staining, the OpalTM 7-color fluorescent IHC kit was used according to the manual provided. Tissue microarrays were sequentially stained with primary antibodies and HRP-conjugated secondary antibodies. One of the four Opal reagents including Dyes Opal520, Opal620, Opal650, and Opal690 were used for staining, followed by microwave treatment and another round of staining. Anti-human CD45 (1:500, GM070129, Gene Tech), anti-human CD4 (1:500, GT219259, Gene Tech), anti-human CD8 (1:300, ab17147, Abcam), anti-human VISTA (1:500, ab230950, Abcam), anti-human CK (1:2000, ab215838, Abcam) were used as primary antibodies. Samples were visualized using the Vectra Automated Quantitative Pathology Imaging System (PerkinElmer).

**Flow cytometry**

Fresh samples, including tumor tissues (n = 33) and peritumor tissues (n = 33) from NSCLC patients were collected from Weifang Second People’s Hospital. The peritumor area was defined with a radius of at least 2 cm from the tumor periphery.

Single-cell suspensions were prepared from tumor tissue. Then samples were stained with anti-human VISTA (PE, clone: MIH65, BD Pharmingen), anti-human CD45 (PC5.5, clone: J33, Beckman Coulter), anti-human CD4 (APC, clone: 13B8.2, Beckman Coulter), anti-human CD8 (APC-A750, clone: B9.11, Beckman Coulter) for 30 minutes at 4°C after being lysed with erythrocyte lysis buffer. Stained cells were washed and resuspended in phosphate-buffered saline. Flow cytometry data were analyzed by FlowJo software (BD, Bioscience).

**Cytokine determination by cytometric bead array (CBA)**

Tumor tissue and peritumor tissue (100 mg) were lysed by Ultrasonic Sonicator (Virsonic 60). Cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, TNF-α, IFN-γ, and IFN-α were measured in lung homogenates supernatant using the human cytokines combined detection kit (Jiangxi Cell-Gene Biotech CO., LTD) and were analyzed by software FCAP Array 3.0 (BD Biosciences) after collection of events in a flow cytometer (Beckman Coulter).

**Ethical statement**

All procedures performed in studies involving human participants were in accordance with the institutional and/or national research committee’s ethical standards and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This study was approved by the Ethics Committee of Weifang Second People’s Hospital (approval number ky2019-004-01) and was carried out according to the guidelines of the Declaration of Helsinki.

**Statistical analysis**

The survival curves were estimated by the Kaplan-Meier method. The Cox regression models were used to study the relationships between correlations and NSCLC OS. Data were analyzed using χ2 test and unpaired t-test. The statistical significance was defined as p < 0.05.
RESULTS

VISTA co-localizes with lymphocytes in tumor tissues of NSCLC patients

The expression of VISTA in samples of NSCLC patients was identified by IHC and multicolor fluorescence immunostaining. The results showed that all 140 tumor specimens from NSCLC patients showed positive VISTA staining (representative figure shown in Figure 1A). To investigate the expression of VISTA in different immune cells, we have developed a new multiplex immunolabelling protocol with Tyramide Signal Amplification. The multicolor fluorescence immunostaining results showed that VISTA co-localized with CD45+, CD4+, and CD8+ staining lymphocytes (Figure 1B and C). These results confirmed the existence of VISTA in NSCLC lymphocytes.

CD4+ VISTA+ T cells expression is increased in tumor tissue compared with the corresponding peritumor tissue

To verify the expression pattern of VISTA in fresh NSCLC tumor tissues, we analyzed the expression of VISTA in freshly collected tissues and its paired peritumor tissues by flow cytometry. The results showed that CD4+ VISTA+ T cells were significantly increased in tumor tissues compared to peritumor tissues (Figure 2A and B), while no significant difference was seen with CD45+ VISTA+ cells and CD8+ VISTA+ T cells (Figure 2C and F).

Expression level of CD4+ VISTA+ T cells correlates with NSCLC progression and may be a prognosticator for survival outcome

We analyzed the expression of VISTA in 106 NSCLC patients undergoing surgical treatment at different TNM

![FIGURE 1. V-domain immunoglobulin suppressor of T-cell activation (VISTA) was expressed in CD45, CD4, and CD8 in non-small cell lung cancer (NSCLC). (A) Immunohistochemistry staining for VISTA in NSCLC tissues. (B) Multicolor fluorescence immunostaining for VISTA (green), CD45 (pink), CD4 (red), and CK (brown) in NSCLC tissues. (C) Multicolor fluorescence immunostaining for VISTA (green), CD8 (cyan), CD4 (red), and CK (brown) in NSCLC tissues.](Image)
The patient characteristics and tumor pathological features are presented in Table 1. The ratio of patients with CD4+ VISTA+ T cells infiltration increased with advanced pathology Node (pN) staging, but no difference was found in pathology Tumor (pT) staging (Figure 3A). Due to the comparatively small number of cases with metastasis, analysis was not performed in this stage.

The prognostic ability of the expression of VISTA on CD4+ T cells was explored next. Among all NSCLC cases with a follow-up of at least 5 years, the OS showed no difference with CD4+ T cell group ($p = 0.6806$, Figure 3B). The high expression of VISTA was related to decreased OS of patients with NSCLC ($p = 0.0352$, Figure 3C). Next, we sought to explore whether the expression of VISTA on CD4+ T cells affects the prognosis of NSCLC patients. The CD4+ VISTA+ T cells group possessed inferior OS than that of the CD4+ VISTA-T cells group ($p = 0.0305$, Figure 3D). These results indicated that the expression of VISTA on CD4+ T cells correlates with NSCLC progression and may be a factor in predicting the survival of NSCLC patients. Univariate Cox regression analysis indicated that node stage ($p < 0.001$), metastasis stage ($p = 0.05$), VISTA expression abundance ($p = 0.02$), and the expression of VISTA on CD4+ T cells ($p = 0.038$) were significantly correlated with OS. Multivariate Cox regression analysis showed that node stage ($p < 0.001$) and VISTA expression abundance ($p = 0.041$) were two independent prognostic factors for OS, while the metastasis stage and the expression of VISTA on CD4+ T cells were not (Table 2).
The expression of VISTA on CD4+ T cells may affect immunity in patients with NSCLC.

Levels of Th1, Th2, regulatory T cells (Tregs), and Th17 and macrophage cytokine secretion in NSCLC patients with VISTA expression on CD4+ T cells were subsequently investigated. We evaluated the cytokine levels of tumor specimens and peritumor specimens in patients with NSCLC. The results showed that the cytokine level in TME of patients with VISTA expression on CD4+ T cells was lower than that in matched adjacent peritumor tissues. Th1 cytokines (IFN-γ, IL-2), Th2 cytokine (IL-4), Tregs cytokine (IL-10), and Th17 cytokine (IL-17) in TME were lower than matched adjacent peritumor tissues (Figure 4A-D). In addition, the level of macrophage cytokine (IL-12p70) in the tumor tissue was significantly reduced compared with the peritumor tissue (Figure 4E). IL-1β, IL-6, IL-8, and IFN-α showed no significant differences (Supplement Figure 2). Together with the results in Figure 4, these data demonstrate that the expression of VISTA on CD4+ T cells should inhibit the function of immune system within the tumor tissue compared with matched adjacent peritumor tissue.

**DISCUSSION**

Immune cells play an important role in the progression of NSCLC. The function of immune cells in the tumor is
Shengyao Ma, et al.: CD4+ VISTA+ T cells are associated with prognosis and immune status of NSCLC

FIGURE 4. The expression of V-domain immunoglobulin suppressor of T-cell activation (VISTA) on CD4+ T cells may affect immunity in patients with non-small cell lung cancer (NSCLC). (A) Expression of Th1 cytokines (IFN-γ, n = 17; IL-2, n = 17) in the tumor tissue compared with the peritumor tissue. (B) The contents of Th2 cytokines (IL-4, n = 17; IL-5, n = 17) in the tumor tissue compared with the peritumor tissue. (C) Expression of Tregs cytokine (IL-10, n = 17) in the tumor tissue compared with the peritumor tissue. (D) The production of Th17 cytokine (IL-17, n = 17) in the tumor tissue compared with the peritumor tissue. (E) The level of macrophage cytokines (IL-12p70, n = 17; TNF-α, n = 17) in the tumor tissue compared with the peritumor tissue. *p < 0.05, **p < 0.01 by unpaired t-test.

primarily divided into two categories: promoting or inhibiting tumor progression. In a study by Catacchio et al. on the association between immune cells and prognosis in lung cancer, it was reported that M2 macrophages, immature dendritic cells, and Treg cells were found to be associated with poor prognosis [14]. Next, we tentatively explored immune cells that were associated with poor prognosis and the mechanism of functional and mechanical barriers. M2 macrophages secreted immunosuppressive cytokines, chemokines, and growth factors to inhibit T-cell activation and promote tumor progression [15,16]. Treg cells also can secrete immunosuppressive cytokines and express cytotoxic T lymphocytes cell antigen-4 (CTLA-4) to impair antitumor immune responses [17,18]. A study showed that oxidative stress can induce apoptosis of Treg cells and release a large amount of adenosine triphosphate, which is metabolized to adenosine through the high expression of CD39 and CD73 in Treg cells. Adenosine binds to A2A receptor (A2AR) to inhibit effector T cells [19]. In lung cancer, the presence of immature dendritic cells led to poor prognosis due to overexpression of programmed cell death-1 (PD-1) and programmed cell death-1L (PD-L1) to inhibit T cell proliferation and activation [20,21]. Myeloid-derived suppressor cells (MDSCs) have been reported to be highly involved in the multistep development of tumorigenesis. MDSC can highly express indoleamine 2,3-dioxygenase (IDO) which can degrade l-tryptophan to N-formylcanine to inhibit T-cell activation and promote CD4+ T cells to differentiate into Treg cells [22]. MDSCs could promote tumor progression through several other mechanisms, such as upregulating PD-L1, secreting immunosuppressive cytokines and growth factors, secreting high levels of vascular endothelial growth factor, and basic fibroblast growth factor (bFGF) [23-25]. These cells contribute to poor progression mainly by inhibiting T-cell activation and proliferation. It is also important to note that the density and activation status of tumor-infiltrating T cells may be critical indicators of prognosis for NSCLC. A study showed that more TILs infiltrated the tumor environment in NSCLC when normally CD4+ T cells account for a large percentage [26]. CD4+ T cells display an antitumor immunity profile by enhancing the antineoplastic effect at the tumor site, preventing activation-induced cell death, and giving priority to the generation of immune memory cells by cytotoxic T-lymphocytes [27]. CD4+ T cells play an important role in
antitumor immunity. However, the potential role of CD4+ T cells in the prognosis of NSCLC is still unclear.

VISTA was identified as a potent inhibitor of T-cell proliferation and activation, which are crucial in immune suppression [11,28-30]. VISTA overexpression in TILs was studied in various cancers, including melanoma [31], gastric cancer [32], and colorectal cancer [33]. Co-localization was prominent in various cancers, including melanoma [31], gastric cancer [32], and colorectal cancer [33]. The expression of VISTA on CD4+ T cells correlated with the immune status of the NSCLC patients. These findings indicated that VISTA might be considered a potential target for NSCLC immunotherapy.

CONCLUSION

In summary, the results of this study indicated that the expression of VISTA on CD4+ T cells was related to poor prognosis in NSCLC patients and may be used as a prognostic factor for adverse NSCLC outcomes. The expression of VISTA on CD4+ T cells correlated with the immune status of the NSCLC patients. These findings indicated that VISTA might be considered a potential target for NSCLC immunotherapy.

ACKNOWLEDGMENTS

The authors would like to thank the Weifang Second People’s Hospital for providing the experimental samples and sample information.

REFERENCES

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):294-308. https://doi.org/10.3322/caac.21660
[2] Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer 2014;14(8):535-46. https://doi.org/10.1038/nrc3775
[3] Del Prete A, Schioppa T, Tiberio L, Stabile H, Sozzani S. Leukocyte trafficking in tumor microenvironment. Curr Opin Pharmacol 2017;35:40-7. https://doi.org/10.1016/j.coph.2017.05.004
[4] Argentiore A, De Summa S, Di Fonte R, Iacobazzi RM, Porcelli L, D’Amato A, et al. Gene expression comparison between the lymph node-positive and-negative reveals a peculiar immune microenvironment signature and a theranostic role for WNT targeting in pancreatic ductal adenocarcinoma: A pilot study. Cancers (Basel) 2019,11(7):942. https://doi.org/10.3390/cancers11070942
[5] Korneev KV, Atrethkina KN, Drutsaikaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorgenesis. Cytokine 2017;89:127-35. https://doi.org/10.1016/j.cytol.2016.01.021
[6] Wang JJ, Lei KF, Han F. Tumor microenvironment: Recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci 2018;22(12):3855-64. https://doi.org/10.26355/eurrev_201806_35720
[7] Song J, Suh WK. The CD28-B7 family in anti-tumor immunity: Emerging concepts in cancer immunotherapy. Immune Netw 2014;14(6):265-76. https://doi.org/10.4101/in.2014.14.6.265
[8] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-99. https://doi.org/10.1016/j.cell.2010.01.025

TABLE 2. Univariate and multivariate analyses of prognostic parameters in 106 NSCLC patients by Cox-regression analysis

| Variables                | Univariate |                      | Multivariate |                      |
|--------------------------|------------|-----------------------|--------------|-----------------------|
|                         | p          | HR (95%CI)            | p            | HR (95%CI)            |
| Gender                   |            |                       |              |                      |
| Male vs Female           | 0.727      | 1.122 (0.588–2.142)   |              |                      |
| Age                      | 0.390      | 1.330 (0.694–2.549)   | 1.501        | 0.050* 1.122 (0.588–2.142) |
| Smoking                  | 0.143      | 0.598 (0.300–1.191)   |              |                      |
| Tumor size               |            |                       |              |                      |
| T1 vs T2-T4              | 0.564      | 1.238 (0.599–2.559)   |              |                      |
| Node stage               |            |                       |              |                      |
| N0 vs N1-N3              | 0.000*     | 5.590 (3.055–11.408)  | 0.000*       | 5.526 (2.552–10.824)  |
| Metastasis stage         |            |                       |              |                      |
| M0 vs M1                 | 0.050*     | 2.189 (0.999–4.794)   | 0.810        | 0.901 (0.387–2.101)   |
| CD4+ TIL                 |            |                       |              |                      |
| High vs Low              | 0.177      | 1.572 (0.815–3.031)   |              |                      |
| VISTA expression abundance|            |                       |              |                      |
| High vs Low              | 0.020*     | 2.225 (1.132–4.371)   | 0.041*       | 2.074 (1.044–4.119)   |
| The expression of VISTA on CD4+ T cells | | | | |
| Positive vs Negative     | 0.038*     | 2.391 (1.050–5.446)   | 0.212        | 1.501 (0.571–3.949)   |

NSCLC: Non-small cell lung cancer, VISTA: V-domain immunoglobulin suppressor of T-cell activation, TIL: Tumor-infiltrating lymphocytes
[9] Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol 2018;25(4):e324-34. https://doi.org/10.3477/2018;25(4):e324-34.

[10] Villarroel-Espindola F, Yu X, Datar I, Mani N, Sammamed M, Velcheti V, et al. Spatially resolved and quantitative analysis of VISTA/PD-1h as a novel immunotherapeutic target in human non-small lung cancer. Clin Cancer Res 2018;24(7):1962-73. https://doi.org/10.1158/0008-5472.CCR-17-2542.

[11] Lines JL, Pantazi E, Mak J, Sampere LF, Wang L, O’Connell S, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 2014;74(7):1904-32. https://doi.org/10.1158/0008-5472.CAN-13-1504.

[12] Nowak EC, Lines JL, Varn FS, Deng J, Sarde A, Mabaera R, et al. Immunoregulatory functions of VISTA. Immunol Rev 2017;276(1):66-79. https://doi.org/10.1111/imr.12525.

[13] Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytokine function of CD8+ T lymphocytes. Cancer Res 2010;70(12):8386-77. https://doi.org/10.1158/0008-5472.CAN-10-3322.

[14] Catacchio I, Scattone A, Silvestris N, Mangia A. Immune prophets of lung cancer: The prognostic and predictive landscape of cellular and molecular immune markers. Transl Oncol 2018;11(3):825-35. https://doi.org/10.1016/j.transolm.2018.04.006.

[15] Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhognagarwa PS, O’Brien S, et al. Human tumor-associated macrophages/microphages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med 2019;11(479):eaat500. https://doi.org/10.1126/scitranslmed.ait500.

[16] Motallebnezhad M, Jadidi-Niaragh F, Qamsari ES, Bagheri S, Motallebnezhad M, Jadidi-Niaragh F, et al. Dendritic cells infiltrating human non-small cell lung cancer show a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. Oncoimmunology 2017;6(1):e1253655.

[17] Shen P, Wang A, He M, Wang Q, Zheng S. Increased circulating lumina-/-low CD3+ CTLA4+ HLA-DR+ myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res 2014;44(6):639-50. https://doi.org/10.1002/hepr.12167.

[18] Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2012;208(3):577-92. https://doi.org/10.1084/jem.20100609.

[19] Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res 2014;74(7):1933-44. https://doi.org/10.1158/0008-5472.CAN-13-1506.

[20] Lines JL, Sampere I, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Immunother 2014;63(6):510-7. https://doi.org/10.1007/s00262-013-1406-9.

[21] Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother 2018;67(4):1185-94. https://doi.org/10.1007/s00262-018-2247-8.

[22] Zhang M, Wang L, Zhao W, Li YE, Yan LX, Dong ZY, et al. VISTA expression associated with CD8+ T cell infiltration in primary non-small cell lung cancer is correlated with poor disease-specific survival. Cancer Immunol Immunother 2018;67(7):1185-94. https://doi.org/10.1007/s00262-018-2247-8.

Related articles published in BJBMSS

1. Three-dimensional telomere profiles in papillary thyroid cancer variants: a pilot study
   Aline Rangel-Pozzo et al., BJBMSS, 2021

2. Follicular morphological characteristics may be associated with invasion in follicular thyroid neoplasms with papillary-like nuclear features
   Nuray Can et al., BJBMSS, 2017

3. Downregulation of TSPAN13 by miR-369-3p inhibits cell proliferation in papillary thyroid cancer (PTC)
   Peng Li et al., BJBMSS, 2019

Bosn J Basic Med Sci. 2022;22(5):707-715
**SUPPLEMENTAL DATA**

**FIGURE S1.** H and E staining of the tumor tissue, intermediate portion, and normal tissue. (A) Pathological characteristics of tumor tissues assessed by H and E staining. (B) H and E staining of intermediate portion. (C) H and E staining of normal tissue.

**FIGURE S2.** The expression of CD4+ T cells may be correlated with the immune status of patients with Non-small cell lung cancer. There was no significant difference in other cytokines.